HoustonEcclestonHolmesIIIMDMBA FACP

Hematology • Dallas, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Holmes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Holmes' full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1026
Is this information wrong?

Education & Training

The University of Texas at DallasMBA, 2013
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Baylor University Medical CenterResidency, Internal Medicine, 1990 - 1993
University of Texas Southwestern Medical SchoolClass of 1990
Stanford UniversityBS, Medical Microbiology, 1981 - 1985

Certifications & Licensure

TX State Medical License 1991 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACP) American College of Physicians, 2000
Top MD Consumers Checkbook
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) Start of enrollment: 2016 Mar 07
Completed
Phase 1, Phase 2
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Active, not recruiting
Phase 1, Phase 2
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Start of enrollment: 2019 May 07
Active, not recruiting
Phase 3
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas Start of enrollment: 2018 Oct 23
Completed
Phase 3
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Start of enrollment: 2018 Nov 15
Terminated
Phase 1
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 3
A Phase 1 Study of ADI-001 in B Cell Malignancies Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Roles: Contact
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Aaron T Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati G...> ;Blood Advances. 2024 Mar 26
68 citations
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A Mc...> ;Journal of Clinical Oncology. 2023 Jan 20
80 citations
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C Logan, Maria R. Baer, William B. Donnellan, Kristen M. O'Dwyer, Houston Holmes, Martha Arellano, Armin G...> ;Blood. 2021 Jul 8
232 citations
Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation
John E. Levine, Thomas Braun, Samuel L. Penza, Patrick Beatty, Kenneth Cornetta, Rodrigo Martino, William R. Drobyski, A. John Barrett, David L. Porter, Sergio Giralt,...> ;Journal of Clinical Oncology. 2002 Jan 15
824 citations
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter...> ;The New England Journal of Medicine. 2020 Apr 1
4 citations
Breast implant-associated anaplastic large cell lymphoma.
Lindsay Keith, William Herlihy, Houston Holmes, Paul G Pin> ;Proceedings. 2017 Oct 1
8 citations
CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus
Shirley Michelle Shiller, Arthur W. Zieske, Houston Holmes, Andrew L. Feldman, Mark E. Law, Rana Saad> ;Cancer Genetics. 2011 Mar 1
26 citations
Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracy...
Edward Agura, Barry Cooper, Houston Holmes, Estil Vance, Robert Brian Berryman, Christopher Maisel, Sandy Li, Giovanna Saracino, Mirjana Tadic-Ovcina, Joseph Fay> ;The Oncologist. 2011 Feb 1
28 citations
Composite lymphocyte-rich Hodgkin lymphoma and peripheral T-cell lymphoma associated with Epstein-Barr virus: a case report and review of the literature.
Steven Sanchez, Houston Holmes, Nora Katabi, Joseph T. Newman, Rana Domiatti-Saad, Marvin J. Stone, George J. Netto> ;Archives of Pathology & Laboratory Medicine. 2006 Jan 1
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
Konkle, B. A., Bauer, K. A., Weinstein, R., Greist, A., Holmes, H. E., Bonfiglio, J.> ;Transfusion. 2003 Apr 5
Join now to see all

Journal Articles

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Wang et al, New England Journal of Medicine, 4/2/2020

Abstracts/Posters

Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registration...
Wang et al, ASCO, 6/2020
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Houston Holmes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refract...
Shah et al, ASCO, 6/2019
Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult ...
Shah et al, ASCO, 6/2018
Join now to see all

Lectures

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a No...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and ExpositionDecember 2nd, 2020
Treating Cancer with Immunotherapy in DFW – One Year LaterJune 9th, 2019